<p>Roivant Sciences（纳斯达克股票代码：ROIV - 获取免费报告）在周一发布给投资者的研究报告中，股票分析师将其目标价格从 24.00 美元上调至 33.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。高盛集团的目标价格暗示该公司股价有 50.10% 的上涨潜力。</p>
<p>获取 <strong>Roivant Sciences</strong> 的提醒：</p>
<ul>
<li>特朗普指数：6 家与特朗普内阁相关的公司值得关注</li>
</ul>
<p>其他一些股票研究分析师最近也对 ROIV 发表了看法。摩根大通将 Roivant Sciences 的目标价格从 16.00 美元上调至 20.00 美元，并在 9 月 18 日的报告中给予该股票 “超配” 评级。华尔街禅在 11 月 16 日的研究报告中将 Roivant Sciences 的评级从 “强烈卖出” 上调至 “持有”。古根海姆在 11 月 14 日的研究报告中重申了 “买入” 评级，并设定了 25.00 美元的目标价格。花旗集团在 11 月 11 日的报告中将 Roivant Sciences 的目标价格从 25.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在周五的研究报告中将 Roivant Sciences 的目标价格从 23.00 美元上调至 26.00 美元，并给予公司 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，七位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 24.81 美元。</p>
<p><strong>获取我们对 ROIV 的最新分析</strong></p>
<h2>Roivant Sciences 股票下跌 0.5%</h2>
<p>周一，Roivant Sciences 的股票在交易时段内下跌 0.12 美元，达到 21.99 美元。该公司股票的交易量为 3,348,188 股，而其平均交易量为 6,537,190 股。该公司的 50 日简单移动平均线为 19.38 美元，200 日简单移动平均线为 14.73 美元。Roivant Sciences 的 12 个月低点为 8.73 美元，12 个月高点为 22.56 美元。该公司的市值为 152.9 亿美元，市盈率为-39.19，贝塔值为 1.22。</p>
<h2>Roivant Sciences 的内部交易</h2>
<p>在其他 Roivant Sciences 的新闻中，主要股东 Vivek Ramaswamy 在 11 月 17 日的交易中出售了 539,650 股 Roivant Sciences 的股票。该股票以平均价格 20.51 美元出售，总交易额为 11,068,221.50 美元。交易完成后，该内部人士在公司持有 33,653,756 股，价值约 690,238,535.56 美元。此次交易使其持股减少了 1.58%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。此外，董事 Daniel Allen Gold 在 11 月 19 日的交易中出售了 1,300,000 股公司的股票。该股票以平均价格 20.23 美元出售，总价值为 26,299,000.00 美元。出售后，该董事直接持有 18,047,727 股公司的股票，价值为 365,105,517.21 美元。这代表其持股减少了 6.72%。此次出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了价值 125,271,540 美元的 6,907,812 股公司股票。公司内部人士持有该公司股票的 10.80%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近调整了对该股票的持有。Allworth Financial LP 在第三季度将其在 Roivant Sciences 的持仓增加了 48.1%。Allworth Financial LP 现在持有 1,795 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 583 股。瑞士人寿资产管理有限公司在第三季度购买了价值约 217,000 美元的 Roivant Sciences 新股份。丹麦银行在第三季度购买了价值 138,000 美元的 Roivant Sciences 新股份。XTX Topco Ltd 在第三季度购买了价值 1,067,000 美元的 Roivant Sciences 新股份。最后，Alyeska Investment Group L.P.在第三季度将其在 Roivant Sciences 的持仓增加了 326.7%。Alyeska Investment Group L.P.现在持有 494,455 股该公司的股票，价值 7,481,000 美元，此前在此期间购买了 378,589 股。对冲基金和其他机构投资者持有该公司股票的 64.76%。</p>
<h2>Roivant Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Roivant Sciences Ltd.是一家商业阶段的生物制药公司，专注于开发和商业化用于炎症和免疫学领域的药物。该公司提供 Vants，一种开发和商业化其药物和技术的模型，专注于生物制药业务、发现阶段公司和健康科技初创企业。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Roivant Sciences</li>
<li>3 只沃伦·巴菲特现在值得购买的股票</li>
<li>随着资本轮换和领导层变动，金融行业突破</li>
<li>股票拆分意味着什么？</li>
<li>超级微型公司的抛售是海市蜃楼——这里是为什么反弹可能会迅速回归</li>
<li>动荡市场中的资产配置策略</li>
<li>3 家公司将大现金流转化为更大的股东收益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Roivant Sciences 吗？</h2>
<p>在考虑 Roivant Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Roivant Sciences 并不在名单上。</p>
<p>虽然 Roivant Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ROIV

<p>高盛将 Roivant Sciences 的目标股价从 24.00 美元上调至 33.00 美元，维持 “买入” 评级，暗示有 50.10% 的上涨空间。其他分析师也调整了他们的目标，摩根大通为 20.00 美元，花旗为 26.00 美元，古根海姆为 25.00 美元。内部交易包括主要股东 Vivek Ramaswamy 出售股份，以及机构投资者调整其持股。Roivant Sciences 专注于炎症和免疫学领域的生物制药</p>

<p>Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price target hoisted by stock analysts at The Goldman Sachs Group from $24.00 to $33.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. The Goldman Sachs Group's price target suggests a potential upside of 50.10% from the company's previous close.</p>
<div class="lb-trans"><p>Roivant Sciences（纳斯达克股票代码：ROIV - 获取免费报告）在周一发布给投资者的研究报告中，股票分析师将其目标价格从 24.00 美元上调至 33.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。高盛集团的目标价格暗示该公司股价有 50.10% 的上涨潜力。</p>
</div><p>Get <strong>Roivant Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Roivant Sciences</strong> 的提醒：</p>
</div><ul>
<li>Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普指数：6 家与特朗普内阁相关的公司值得关注</li>
</ul>
</div><p>A number of other equities research analysts also recently weighed in on ROIV. JPMorgan Chase &amp; Co. lifted their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, September 18th. Wall Street Zen upgraded shares of Roivant Sciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, November 16th. Guggenheim reiterated a &#34;buy&#34; rating and set a $25.00 target price on shares of Roivant Sciences in a research report on Friday, November 14th. Citigroup raised their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, November 11th. Finally, HC Wainwright lifted their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $24.81.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对 ROIV 发表了看法。摩根大通将 Roivant Sciences 的目标价格从 16.00 美元上调至 20.00 美元，并在 9 月 18 日的报告中给予该股票 “超配” 评级。华尔街禅在 11 月 16 日的研究报告中将 Roivant Sciences 的评级从 “强烈卖出” 上调至 “持有”。古根海姆在 11 月 14 日的研究报告中重申了 “买入” 评级，并设定了 25.00 美元的目标价格。花旗集团在 11 月 11 日的报告中将 Roivant Sciences 的目标价格从 25.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在周五的研究报告中将 Roivant Sciences 的目标价格从 23.00 美元上调至 26.00 美元，并给予公司 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，七位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 24.81 美元。</p>
</div><p><strong>Get Our Latest Analysis on ROIV</strong></p>
<div class="lb-trans"><p><strong>获取我们对 ROIV 的最新分析</strong></p>
</div><h2>Roivant Sciences Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Roivant Sciences 股票下跌 0.5%</h2>
</div><p>Roivant Sciences stock traded down $0.12 during trading hours on Monday, reaching $21.99. 3,348,188 shares of the company's stock were exchanged, compared to its average volume of 6,537,190. The firm's 50 day simple moving average is $19.38 and its 200 day simple moving average is $14.73. Roivant Sciences has a twelve month low of $8.73 and a twelve month high of $22.56. The firm has a market capitalization of $15.29 billion, a PE ratio of -39.19 and a beta of 1.22.</p>
<div class="lb-trans"><p>周一，Roivant Sciences 的股票在交易时段内下跌 0.12 美元，达到 21.99 美元。该公司股票的交易量为 3,348,188 股，而其平均交易量为 6,537,190 股。该公司的 50 日简单移动平均线为 19.38 美元，200 日简单移动平均线为 14.73 美元。Roivant Sciences 的 12 个月低点为 8.73 美元，12 个月高点为 22.56 美元。该公司的市值为 152.9 亿美元，市盈率为-39.19，贝塔值为 1.22。</p>
</div><h2>Insider Transactions at Roivant Sciences</h2>
<div class="lb-trans"><h2>Roivant Sciences 的内部交易</h2>
</div><p>In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $20.51, for a total transaction of $11,068,221.50. Following the completion of the transaction, the insider owned 33,653,756 shares in the company, valued at approximately $690,238,535.56. The trade was a 1.58% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00. Following the sale, the director directly owned 18,047,727 shares of the company's stock, valued at $365,105,517.21. This represents a 6.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,907,812 shares of company stock valued at $125,271,540 over the last three months. Corporate insiders own 10.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Roivant Sciences 的新闻中，主要股东 Vivek Ramaswamy 在 11 月 17 日的交易中出售了 539,650 股 Roivant Sciences 的股票。该股票以平均价格 20.51 美元出售，总交易额为 11,068,221.50 美元。交易完成后，该内部人士在公司持有 33,653,756 股，价值约 690,238,535.56 美元。此次交易使其持股减少了 1.58%。该交易已在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。此外，董事 Daniel Allen Gold 在 11 月 19 日的交易中出售了 1,300,000 股公司的股票。该股票以平均价格 20.23 美元出售，总价值为 26,299,000.00 美元。出售后，该董事直接持有 18,047,727 股公司的股票，价值为 365,105,517.21 美元。这代表其持股减少了 6.72%。此次出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了价值 125,271,540 美元的 6,907,812 股公司股票。公司内部人士持有该公司股票的 10.80%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after buying an additional 583 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Roivant Sciences during the third quarter valued at approximately $217,000. Danske Bank A S bought a new stake in Roivant Sciences during the third quarter worth $138,000. XTX Topco Ltd purchased a new position in Roivant Sciences in the third quarter worth $1,067,000. Finally, Alyeska Investment Group L.P. grew its stake in Roivant Sciences by 326.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company's stock valued at $7,481,000 after purchasing an additional 378,589 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。Allworth Financial LP 在第三季度将其在 Roivant Sciences 的持仓增加了 48.1%。Allworth Financial LP 现在持有 1,795 股该公司的股票，价值 27,000 美元，此前在上个季度购买了 583 股。瑞士人寿资产管理有限公司在第三季度购买了价值约 217,000 美元的 Roivant Sciences 新股份。丹麦银行在第三季度购买了价值 138,000 美元的 Roivant Sciences 新股份。XTX Topco Ltd 在第三季度购买了价值 1,067,000 美元的 Roivant Sciences 新股份。最后，Alyeska Investment Group L.P.在第三季度将其在 Roivant Sciences 的持仓增加了 326.7%。Alyeska Investment Group L.P.现在持有 494,455 股该公司的股票，价值 7,481,000 美元，此前在此期间购买了 378,589 股。对冲基金和其他机构投资者持有该公司股票的 64.76%。</p>
</div><h2>Roivant Sciences Company Profile</h2>
<div class="lb-trans"><h2>Roivant Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.</p>
<div class="lb-trans"><p>Roivant Sciences Ltd.是一家商业阶段的生物制药公司，专注于开发和商业化用于炎症和免疫学领域的药物。该公司提供 Vants，一种开发和商业化其药物和技术的模型，专注于生物制药业务、发现阶段公司和健康科技初创企业。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Roivant Sciences</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Financial Sector Breaks Out as Capital Rotates and Leadership Shifts</li>
<li>What Does a Stock Split Mean?</li>
<li>Super Micro's Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Roivant Sciences</li>
<li>3 只沃伦·巴菲特现在值得购买的股票</li>
<li>随着资本轮换和领导层变动，金融行业突破</li>
<li>股票拆分意味着什么？</li>
<li>超级微型公司的抛售是海市蜃楼——这里是为什么反弹可能会迅速回归</li>
<li>动荡市场中的资产配置策略</li>
<li>3 家公司将大现金流转化为更大的股东收益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk9JVg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ROIV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Roivant Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Roivant Sciences 吗？</h2>
</div><p>Before you consider Roivant Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Roivant Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Roivant Sciences 并不在名单上。</p>
</div><p>While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Roivant Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Roivant Sciences（纳斯达克股票代码：ROIV）被高盛集团给予新的目标价 33.00 美元